Dr. Suchismita Acharya started AyuVis because of her passion to find a solution to the problem of antibiotic resistance to drugs and to target the unmet clinical needs in life-threatening indications.
The company’s lead program started in the antibiotic/immunomodulatory space to treat bacterial induced hospital-based complicated Intra-Abdominal Infections (cIAI), a critical infectious disease which exhibits high rates of bacterial resistance and high patient morbidity and death. The company since then has expanded its research significantly towards Bronchopulmonary Dysplasia (BPD).
AyuVis team members share the company’s focus and ambitious goals for addressing unmet clinical needs and finding solutions to treat patients who suffer from inflammatory and infectious diseases.
The scientific advisery board includes experts in the field of immunomodulation and the respiratory system and are widely recognized for substantial contributions in their fields of research.
Board of Directors
AyuVis' Board of Directors bring both breadth and depth of experience in their respective fields and share their wealth of expertise in advancing our objectives.